Truist Securities Maintains Hold on Globus Medical, Raises Price Target to $79
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter maintains a Hold rating on Globus Medical (NYSE:GMED) and raises the price target from $78 to $79.
August 07, 2024 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities maintains a Hold rating on Globus Medical and raises the price target from $78 to $79.
The raised price target indicates a slightly more positive outlook on Globus Medical's stock, which could lead to a minor uptick in investor sentiment and short-term stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100